Mirum Pharmaceuticals third quarter 2026 revenue of $185.7M beat estimates as 2026 sales guidance was raised

Mirum Pharmaceuticals reported third quarter 2026 financial results characterized by a 40% year-over-year increase in total revenue, outperforming analyst expectations. The growth was driven by strong demand for LIVMARLI and steady contributions from the Bile Acid Medicines portfolio, prompting management to raise full-year product sales guidance.

Key Highlights

• Global net product sales reached $185.7 million, exceeding the consensus estimate of $178.1 million.
• LIVMARLI revenue grew 45% year-over-year to $133.4 million, reflecting expanded market penetration for Alagille syndrome and PFIC.
• Increased 2026 net product sales guidance to a range of $715 million to $720 million, up from previous internal projections.
• Operating expenses rose to $245.5 million, driven by $93.6 million in R&D spend and $40.0 million in non-cash items including stock-based compensation.
• Cash and investments totaled $500.5 million as of September 30, 2026, following the launch of ATEBRIOZ for FOP and positive clinical readouts.